Want to see IN:LALPATHLAB full AI Analyst Report?
LALPATHLAB Stock Chart & Stats
₹1472.95
-₹106.10(-3.42%)
At close: 4:00 PM EST
₹1472.95
-₹106.10(-3.42%)
Day’s Range― - ―
52-Week Range₹1,272.00 - ₹1,803.60
Previous CloseN/A
Volume152.98K
Average Volume (3M)3.61K
Market Cap
₹276.12B
Enterprise Value₹268.71B
Total Cash (Recent Filing)₹13.02B
Total Debt (Recent Filing)₹2.55B
Price to Earnings (P/E)54.5
Beta0.59
Next Earnings
Jul 24, 2026EPS Estimate
8.71Next Dividend Ex-DateN/A
Dividend Yield0.89%
Share Statistics
EPS (TTM)32.04
Shares Outstanding167,637,770
10 Day Avg. Volume2,182
30 Day Avg. Volume3,614
Financial Highlights & Ratios
PEG Ratio12.69
Price to Book (P/B)8.73
Price to Sales (P/S)7.93
P/FCF Ratio40.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)35.23
Revenue Forecast (FY)₹31.31B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage (debt-to-equity ~0.08) materially improves financial flexibility and reduces interest risk. This durable strength lets the company fund organic network growth, absorb cyclical shocks or fund targeted investments without heavy external financing, supporting long-term stability.
Strong Operating Cash GenerationOperating cash flow that exceeds net income and coverage ~1.56 indicates high earnings quality and internal funding ability. Reliable cash generation supports reinvestment in labs, technology and collection network, sustaining growth without reliance on capital markets over the medium term.
Integrated Lab & Collection NetworkA broad network of labs and collection centers creates durable scale advantages in sample throughput, logistics and customer reach. This asset footprint supports high-volume routine testing, B2B contracts and cross-selling of specialized assays, reinforcing competitive position over months to years.
Bears Say
FY2026 Margin CompressionSharp gross-margin pressures and a dip in net margin in FY2026 signal persistent cost or pricing headwinds. Sustained margin erosion would reduce reinvestment capacity and ROE, making earnings growth more sensitive to volume and hampering long-term profitability unless structural cost actions or pricing improvements follow.
Weaker Free Cash Flow ConversionDeclining FCF conversion and historical swings show working capital and capex can be lumpy. If conversion remains below prior levels, the company may have less internal funding for expansion or dividends, increasing reliance on capital or delaying strategic initiatives during adverse periods.
Slowing Revenue GrowthA deceleration from ~10% to ~6% top-line growth suggests the company faces tougher market saturation, competitive pricing or lower incremental demand. Sustained slower growth would constrain operating leverage benefits and require stronger margin or new-service expansion to maintain long-term earnings momentum.
Dr. Lal PathLabs Limited News
LALPATHLAB FAQ
What was Dr. Lal PathLabs Limited’s price range in the past 12 months?
Dr. Lal PathLabs Limited lowest stock price was ₹1272.00 and its highest was ₹1803.60 in the past 12 months.
What is Dr. Lal PathLabs Limited’s market cap?
Dr. Lal PathLabs Limited’s market cap is ₹276.12B.
When is Dr. Lal PathLabs Limited’s upcoming earnings report date?
Dr. Lal PathLabs Limited’s upcoming earnings report date is Jul 24, 2026 which is in 22 days.
How were Dr. Lal PathLabs Limited’s earnings last quarter?
Dr. Lal PathLabs Limited released its earnings results on Apr 30, 2026. The company reported ₹7.865 earnings per share for the quarter, beating the consensus estimate of ₹7.247 by ₹0.618.
Is Dr. Lal PathLabs Limited overvalued?
According to Wall Street analysts Dr. Lal PathLabs Limited’s price is currently Overvalued.
Does Dr. Lal PathLabs Limited pay dividends?
Dr. Lal PathLabs Limited pays a Quarterly dividend of ₹4 which represents an annual dividend yield of 0.89%. See more information on Dr. Lal PathLabs Limited dividends here
What is Dr. Lal PathLabs Limited’s EPS estimate?
Dr. Lal PathLabs Limited’s EPS estimate is 8.71.
How many shares outstanding does Dr. Lal PathLabs Limited have?
Dr. Lal PathLabs Limited has 167,637,770 shares outstanding.
What happened to Dr. Lal PathLabs Limited’s price movement after its last earnings report?
Dr. Lal PathLabs Limited reported an EPS of ₹7.865 in its last earnings report, beating expectations of ₹7.247. Following the earnings report the stock price went down -2.104%.
Which hedge fund is a major shareholder of Dr. Lal PathLabs Limited?
Currently, no hedge funds are holding shares in IN:LALPATHLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited is a leading provider of diagnostic and related health assessment services, operating both domestically in India and across international borders. The company manages a comprehensive network of laboratories dedicated to conducting pathological investigations across various specialized fields. These include biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, in addition to other general pathological and radiological studies. Beyond its core testing operations, Dr. Lal PathLabs also offers laboratory staff training, technical support, and full-scale lab management services. As of March 31, 2022, its widespread infrastructure included 277 clinical laboratories, notably a National Reference Lab located in Delhi and a Regional Reference Lab in Kolkata. This is further bolstered by 4,731 patient service centers and 10,599 sample collection points. Founded in 1949, Dr. Lal PathLabs Limited maintains its corporate base in Gurugram, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―
Vimta Labs Limited
―